Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 3/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.40 |
| ▸ | CTSA | P10619 | 1/20 | 0.38 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.33 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11427001 | 0.85 | KDM4E (0.36) | GRM5SIRT6HCAR2NAPRTKDM4E | |
| SCHEMBL27858703 | 0.84 | GRM5 (0.49) | GRM5CDK2S1PR3CTSASIRT6 | |
| SCHEMBL29913176 | 0.82 | GRM5 (0.47) | GRM5CDK2S1PR3CTSASIRT6 | |
| SCHEMBL376147 | 0.82 | GRM5 (0.47) | GRM5CDK2S1PR3CTSASIRT6 | |
| SCHEMBL12091007 | 0.80 | GRM5 (0.46) | GRM5CDK2S1PR3CTSASIRT6 | |
| SCHEMBL741061 | 0.80 | SIRT6 (0.50) | GRM5CDK2S1PR3CTSASIRT6 | |
| SCHEMBL31555012 | 0.80 | SIRT6 (0.50) | GRM5CDK2S1PR3CTSASIRT6 | |
| SCHEMBL30354632 | 0.80 | GRM5 (0.46) | GRM5CDK2S1PR3CTSASIRT6 | |
| SCHEMBL28560032 | 0.77 | CDK2 (0.43) | GRM5CDK2S1PR3CTSAKDM4E | |
| SCHEMBL22711336 | 0.76 | GRM5 (0.49) | GRM5HCAR2KDM4EALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124431-A1 | 2,3-DIHYDRO-4H-BENZO[B][1,4]OXAZIN-4-YL)(5-(PHENYL)-PYRIDIN-3-YL)METHANONE DERIVATIVES AND SIMILAR COMPOUNDS AS CYP11A1 INHIBITORS FOR THE TREATMENT OF PROSTATE CANCER | ORION CORPORATION (FI) | 2024-04-18 | — | — | US | disclosed |
| US-11337973-B2 | Substituted [1,2,4]triazolo[4,3-A]pyrazines as prolyl endopeptidase inhibitors | BAYER AKTIENGESELLSCHAFT (DE) | 2022-05-24 | — | — | US | disclosed |
| US-11337973-B2 | Substituted [1,2,4]triazolo[4,3-A]pyrazines as prolyl endopeptidase inhibitors | BAYER AKTIENGESELLSCHAFT (DE) | 2022-05-24 | — | — | US | disclosed |
| EP-3707141-B1 | SUBSTITUTED 2,4-DIHYDRO-3H-1,2,4-TRIAZOL-3-ONES AND USE OF SAME | BAYER AG (DE) | 2021-12-22 | — | — | EP | disclosed |
| EP-3707141-B1 | SUBSTITUTED 2,4-DIHYDRO-3H-1,2,4-TRIAZOL-3-ONES AND USE OF SAME | BAYER AG (DE) | 2021-12-22 | — | — | EP | disclosed |
| US-20200375986-A1 | SUBSTITUTED 2,4-DIHYDRO-3H-1,2,4-TRIAZOL-3-ONES AND USE OF SAME | BAYER AKTIENGESELLSCHAFT (DE) | 2020-12-03 | — | — | US | disclosed |
| US-20200375986-A1 | SUBSTITUTED 2,4-DIHYDRO-3H-1,2,4-TRIAZOL-3-ONES AND USE OF SAME | BAYER AKTIENGESELLSCHAFT (DE) | 2020-12-03 | — | — | US | disclosed |
| EP-3707141-A1 | SUBSTITUTED 2,4-DIHYDRO-3H-1,2,4-TRIAZOL-3-ONES AND USE OF SAME | Bayer Aktiengesellschaft (DE) | 2020-09-16 | — | — | EP | disclosed |
| US-9682995-B2 | Amino-substituted isothiazoles | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-20 | — | — | US | disclosed |
| EP-2951174-B1 | AMINO-SUBSTITUTED ISOTHIAZOLES | Bayer Pharma AG (DE) | 2017-04-26 | — | — | EP | disclosed |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC (US) | 2011-06-16 | — | — | US | disclosed |
| EP-2328890-A1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | Pfizer Inc. (US) | 2011-06-08 | — | — | EP | disclosed |
| CN-102015720-A | Selective ligands for neuronal nicotinic receptors and uses thereof | ABBOTT LAB | 2011-04-13 | — | — | CN | disclosed |
| EP-2285810-A1 | SELECTIVE LIGANDS FOR THE NEURONAL NICOTINIC RECEPTORS AND USES THEREOF | Abbott Laboratories (US) | 2011-02-23 | — | — | EP | disclosed |
| WO-2010016005-A1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010016005-A1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| US-20090281118-A1 | Selective Ligands for the Neuronal Nicotinic Receptors and Uses Thereof | ABBOTT LABORATORIES (US) | 2009-11-12 | — | — | US | disclosed |
| WO-2009137308-A1 | SELECTIVE LIGANDS FOR THE NEURONAL NICOTINIC RECEPTORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200375986-A1 | SUBSTITUTED 2,4-DIHYDRO-3H-1,2,4-TRIAZOL-3-ONES AND USE OF SAME | PREP, SERPINB1, PEPD | GRM5 3812/4885CDK2 1156/4885S1PR3 1337/4885 |
| US-11337973-B2 | Substituted [1,2,4]triazolo[4,3-A]pyrazines as prolyl endopeptidase inhibitors | PREP, PEPD, SERPINB1 | GRM5 1935/4885CDK2 819/4885S1PR3 1435/4885 |
| US-20240124431-A1 | 2,3-DIHYDRO-4H-BENZO[B][1,4]OXAZIN-4-YL)(5-(PHENYL)-PYRIDIN-3-YL)METHANONE DERIVATIVES AND SIMILAR COMPOUNDS AS CYP11A1 INHIBITORS FOR THE TREATMENT OF PROSTATE CANCER | CYP11B1, CYP11B2, SRD5A1 | GRM5 1639/4885CDK2 447/4885S1PR3 1359/4885 |
| US-20090281118-A1 | Selective Ligands for the Neuronal Nicotinic Receptors and Uses Thereof | CHRNA4, CHRNB4, CHRNA2 | GRM5 64/4885CDK2 2403/4885S1PR3 688/4885 |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | CHKA, CSNK1A1, CHKB | GRM5 4665/4885CDK2 157/4885S1PR3 1445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.